Taysha Gene Therapies, Inc. (TSHA)
NASDAQ:TSHA
Want to see TSHA full AI Analyst Report?
TSHA Stock Chart & Stats
$6.43
-$0.08(-4.26%)
At close: 4:00 PM EST
$6.43
-$0.08(-4.26%)
Day’s Range― - ―
52-Week Range$2.25 - $7.30
Previous CloseN/A
Volume273.02K
Average Volume (3M)2.48M
Market Cap
$1.69B
Enterprise Value$1.21B
Total Cash (Recent Filing)$276.58M
Total Debt (Recent Filing)$17.77M
Price to Earnings (P/E)―
Beta2.61
Next Earnings
Aug 17, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding287,361,020
10 Day Avg. Volume2,340,105
30 Day Avg. Volume2,480,433
Financial Highlights & Ratios
PEG Ratio2.90
Price to Book (P/B)7.12
Price to Sales (P/S)179.93
P/FCF Ratio-18.74
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue161.96
Enterprise Value/Gross Profit183.59
Enterprise Value/Ebitda-9.29
Forecast
1Y Price Target
$12.67Price Target Upside96.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$3.16M
Bulls Say, Bears Say
Bulls Say
Clinical Safety And Efficacy SignalsShared patient data showing at least one developmental milestone gain and a clean safety profile support early efficacy and tolerability signals for the gene therapy.
Commercial DifferentiationPhysician and caregiver preference for the therapy's less invasive intrathecal delivery versus a competitor supports potential commercial uptake and market differentiation.
Regulatory PathwayFDA agreement on the study's statistical analysis plan and allowance to include younger patients strengthens the regulatory pathway and supports potential approval covering a broader patient group.
Bears Say
Data Timing And Disclosure RiskManagement's plan to release interim pivotal data only after a pre‑BLA meeting with regulators creates uncertainty around the timing and public availability of key trial results.
Research ObjectivityDeclared conflicts of interest tied to investment bank business relationships may reduce confidence in the objectivity of analyst reports and complicate investor interpretation of research signals.
Scientific Validation RiskThe pre‑printed comprehensive analysis has not completed peer review and requires additional validation, introducing uncertainty about the robustness of supporting scientific evidence.
Taysha Gene Therapies News
TSHA FAQ
What was Taysha Gene Therapies, Inc.’s price range in the past 12 months?
Taysha Gene Therapies, Inc. lowest stock price was $2.25 and its highest was $7.30 in the past 12 months.
What is Taysha Gene Therapies, Inc.’s market cap?
Taysha Gene Therapies, Inc.’s market cap is $1.69B.
When is Taysha Gene Therapies, Inc.’s upcoming earnings report date?
Taysha Gene Therapies, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 78 days.
How were Taysha Gene Therapies, Inc.’s earnings last quarter?
Taysha Gene Therapies, Inc. released its earnings results on May 06, 2026. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.097 by -$0.023.
Is Taysha Gene Therapies, Inc. overvalued?
According to Wall Street analysts Taysha Gene Therapies, Inc.’s price is currently Undervalued.
Does Taysha Gene Therapies, Inc. pay dividends?
Taysha Gene Therapies, Inc. does not currently pay dividends.
What is Taysha Gene Therapies, Inc.’s EPS estimate?
Taysha Gene Therapies, Inc.’s EPS estimate is -0.12.
How many shares outstanding does Taysha Gene Therapies, Inc. have?
Taysha Gene Therapies, Inc. has 287,361,020 shares outstanding.
What happened to Taysha Gene Therapies, Inc.’s price movement after its last earnings report?
Taysha Gene Therapies, Inc. reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.097. Following the earnings report the stock price went up 0.576%.
Which hedge fund is a major shareholder of Taysha Gene Therapies, Inc.?
Currently, no hedge funds are holding shares in TSHA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Taysha Gene Therapies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.67 (96.99% Upside)
$12.67 (96.99% Upside)
Blogger Sentiment
Bullish
TSHA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 322.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
113.45%
12-Months-Change
Fundamentals
Return on Equity
-56.07%
Trailing 12-Months
Asset Growth
117.08%
Trailing 12-Months
Company Description
Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
TSHA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical, preclinical and regulatory momentum for TSHA-102 — including FDA alignment on a potential expedited pathway, robust Part A efficacy signals (high response rates, multiple developmental milestones and functional gains), initiation of BLA-enabling PPQ, and a solid cash position with runway into 2028. These positives are tempered by materially higher R&D and G&A spending that drove a near-doubling of net loss year-over-year, ongoing uncertainty around whether the FDA will accept a 6-month interim for full approval versus requiring 12-month data, and the need to complete PPQ and validate manufacturing redundancy. Overall, the operational and scientific progress appears to outweigh the financial and timing risks at this stage.View all TSHA earnings summariesTSHA Stock 12 Month Forecast
Average Price Target
$12.67
▲(96.99% Upside)
Technical Analysis
Relay Therapeutics
―
Immunome
―
ARS Pharmaceuticals
―
Sana Biotechnology
―
Prime Medicine, Inc.
―
Ownership Overview
12.21% Insiders
9.37% Mutual Funds
45.38% Other Institutional Investors
21.20% Public Companies and
Individual Investors